Background: Malignancies after solid organ transplantation are more common than in the general population. According to the International Society for Heart and Lung Transplantation (ISHLT),  malignancies are the second leading cause of death 5 years after lung transplant. 
Malignancies have been described more commonly in lung transplant recipients compared to other solid organ transplants, probably due to the greater degree   of immunosuppression. Skin cancer, post transplan lymphoproliferative disorder and lung cancer of the native lung have been described as leading diagnosis.
We aimed to describe our experience in a large academic facility in Argentina.
Methods: Retrospective single center study. Using electronic medical records, we evaluated all adult lung transplants performed from January 1st 2010 to December 31 2022. Patients surviving less than one year were excluded. Demographic data was recorded.
Results: 101 lung transplants were performed in 100 patients. 75 patients survived over a year and were included in the analysis. Malignancies were diagnosed in 7 (9%) of patients, as follows: lung cancer (native lung) in 4, colon cancer in 1, gastric cancer in 1 and pancreatic cancer in 1. Median time of cancer onset  from transplantation was 35 months. 5 (71%) of patients died within a year of diagnosis.
Conclusion: Cancer incidence was lower than in others reports. Notably, neither skin cancer nor PTLD were found. Survival after malignancy diagnosis was poor.